TSHA Taysha Gene Therapies

Taysha Gene Therapies to Participate in JMP Securities Hematology and Oncology Summit

Taysha Gene Therapies to Participate in JMP Securities Hematology and Oncology Summit

DALLAS, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced that it will participate in the JMP Securities Hematology and Oncology Summit, which is taking place virtually from Tuesday, December 6, 2022, through Wednesday, December 7, 2022. Taysha’s President, Founder and Chief Executive Officer, RA Session II, will participate in a fire side chat with Silvan Turkan, Ph.D., Senior Research Analyst at JMP Securities, at 3:40 PM ET on Wednesday, December 7, 2022.

A webcast of the fire side chat will be available in the “Events & Media” section of the Taysha corporate website at . An archived version of the webcast will be available on the website for 90 days.

About Taysha Gene Therapies        

Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at .

Company Contact:

Kimberly Lee, D.O.

Chief Corporate Affairs Officer

Taysha Gene Therapies

Media Contact:

Carolyn Hawley

Evoke Canale



EN
29/11/2022

Underlying

TSHATaysha Gene Therapies

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Taysha Gene Therapies

 PRESS RELEASE
Free
TSHA Taysha Gene The...

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing ...

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) DALLAS, April 05, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system (CNS), today announced that, on April 1, 2024, the Compensation Committee of Taysha's Board of Directors granted three new employees, in the aggregate, options to purchase 140,000 shares of the Company's common stock in connection with thei...

April 5, 2024 1 EN
 PRESS RELEASE
Free
TSHA Taysha Gene The...

Taysha Gene Therapies Reports Full Year 2023 Financial Results and Pro...

Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical Updates Data from first adult patient in REVEAL Phase 1/2 trial showed TSHA-102 (low dose, 5.7x1014 total vg) was well-tolerated with no treatment-emergent SAEs as of 35-week assessment, with sustained improvement across key efficacy measures at decreased steroid levels and new improvement in RSBQ at month six Data from second adult patient showed TSHA-102 (low dose, 5.7x1014 total vg) was well-tolerated with no treatment-emergent SAEs as of 19-week assessment, with sustained improvement acro...

March 19, 2024 1 EN
 PRESS RELEASE
Free
TSHA Taysha Gene The...

Taysha Gene Therapies to Release Full-Year 2023 Financial Results, Pro...

Taysha Gene Therapies to Release Full-Year 2023 Financial Results, Provide Corporate and Clinical Updates and Host Conference Call on March 19 DALLAS, March 14, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the full-year ended December 31, 2023, provide corporate and clinical updates and host a c...

March 14, 2024 1 EN
 PRESS RELEASE
Free
TSHA Taysha Gene The...

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing ...

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) DALLAS, March 01, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system (CNS), today announced that, on March 1, 2024, the Compensation Committee of Taysha's Board of Directors granted four new employees, in the aggregate, options to purchase 347,000 shares of the Company's common stock in connection with their...

March 1, 2024 1 EN
 PRESS RELEASE
Free
TSHA Taysha Gene The...

Taysha Gene Therapies Announces Updates to TSHA-102 Clinical Program i...

Taysha Gene Therapies Announces Updates to TSHA-102 Clinical Program in Rett Syndrome REVEAL adolescent and adult trial will proceed to high dose cohort following Independent Data Monitoring Committee approval of Company’s request to initiate dose escalation; dosing of first patient in cohort two (high dose, n=3) expected in Q2 2024 REVEAL adolescent and adult trial will now expand into the U.S. following submission to FDA (age 12+ protocol) Dosing of second patient in cohort one (low dose) of REVEAL pediatric trial expected in Q1 2024 following Independent Data Monitoring Committee ...

February 29, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch